CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Type 2 Diabetes in Youth: Epidemiology and Pathophysiology

Open access
D’Adamo, Ebe, Caprio, Sonia · 2011 · Diabetes Care

Abstract

The prevalence of type 2 diabetes is significantly increased in the pediatric population, which is affected by obesity worldwide. The progression from normal glucose tolerance (NGT) to type 2 diabetes involves intermediate stages of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), also known as prediabetes. The pathophysiology underlying the development of these glucose metabolic alterations is multifactorial; however an alteration in the balance between insulin sensitivity and insulin secretion represents the most important player in the development of type 2 diabetes. Obese children and adolescents affected by IGT and type 2 diabetes are characterized by severe insulin resistance, which is associated with an increased lipid accumulation in visceral compartments, liver and muscle tissues and by reduced sensitivity of I²-cell of first and second-phase insulin secretion. The progression in obese children of insulin resistance to type 2 diabetes has been shown to be faster than in adults; in addition, type 2 diabetes is already associated with several metabolic and cardiovascular complications in this age group. In the present review, we summarize the most recent findings concerning the prevalence of type 2 diabetes in youth and in particular we explore the pathophysiology of type 2 diabetes and the natural history of this pathology in obese children and adolescents. Concurrent with the worldwide epidemic increase of childhood obesity, type 2 diabetes and the two prediabetic conditions, IFG and IGT, are becoming increasingly more common in obese children and adolescents (1,2). Until 10 years ago, type 2 diabetes accounted for less than 3% of all cases of new-onset diabetes in adolescents. At present 45% of cases are attributed to it (3,4). Type 2 diabetes occurs in youth more often during the second decade of life, coinciding with the physiological occurrence of pubertal insulin resistance (1). In addition, …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-s212

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Glucose sensitivity of first-phase (σ1, dynamic secretion component) and second-phase (σ2, static secretion component) insulin secretion among NGT, IFG, IGT, and IFG/IGT obese adolescents. (*P = 0.004 IFG vs. NGT; **P = 0.04 IGT vs. NGT; ***P = 0.0001 IFG/IGT vs. NGT; ♦P = 0.02 IGT vs. NGT).
Figure 1 Glucose sensitivity of first-phase (σ1, dynamic secretion component) and second-phase (σ2, static secretion component) insulin secretion among NGT, IFG, IGT, and IFG/IGT obese adolescents. (*P = 0.004 IFG vs. NGT; **P = 0.04 IGT vs. NGT; ***P = 0.0001 IFG/IGT vs. NGT; ♦P = 0.02 IGT vs. NGT).CC BY-NC-ND · PubMed Central
Figure 2 A: Baseline values of the dynamic β-cell responsivity (Φd) in subjects who maintained NGT (nonprogressors [NP]) and in subjects who developed IGT (progressors [P]) (P = 0.04). B: Changes of the DI values according to changes in glucose tolerance over the course of approximately 30 months. Subjects who developed IGT (progressors) experienced a progressive decline of overall β-cell function, as assessed by the DI. OGTT, oral glucose tolerance test.*P = 0.04.
Figure 2 A: Baseline values of the dynamic β-cell responsivity (Φd) in subjects who maintained NGT (nonprogressors [NP]) and in subjects who developed IGT (progressors [P]) (P = 0.04). B: Changes of the DI values according to changes in glucose tolerance over the course of approximately 30 months. Subjects who developed IGT (progressors) experienced a progressive decline of overall β-cell function, as assessed by the DI. OGTT, oral glucose tolerance test.*P = 0.04.CC BY-NC-ND · PubMed Central
Figure 3 Liver fat content and impairment of insulin sensitivity and β-cell function in obese children and adolescents. The whole-body insulin sensitivity index (WBISI) decreased (P = 0.007) across low (median 0.7%), moderate (median 4.5%), and high (median 28.8%) liver fat content (%) tertiles. The insulinogenic index (IGI) tended to be higher (P = 0.05) and the DI tended to be lower (P = 0.05) in the high tertile compared with the low tertile.
Figure 3 Liver fat content and impairment of insulin sensitivity and β-cell function in obese children and adolescents. The whole-body insulin sensitivity index (WBISI) decreased (P = 0.007) across low (median 0.7%), moderate (median 4.5%), and high (median 28.8%) liver fat content (%) tertiles. The insulinogenic index (IGI) tended to be higher (P = 0.05) and the DI tended to be lower (P = 0.05) in the high tertile compared with the low tertile.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 315

Metadata

Authors
D’Adamo, E., & Caprio, S.
Affiliations
Yale University (US)
Corresponding author
Caprio, Sonia
Venue
Diabetes Care
Published
2011-04-22
Volume
34
Issue
Supplement_2
Pages
S161-S165
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2114855885
Cited by
315
References
36
Citations by year
2026: 5 · 2025: 6 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 30 · 2020: 29 · 2019: 24 · 2018: 33 · 2017: 33 · 2016: 39 · 2015: 22 · 2014: 26 · 2013: 11 · 2012: 12
FWCI
3.01
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Georgia Clinical and Translational Science Alliance
  • Novo Nordisk
  • National Institutes of Health (and K24)
  • National Center for Research Resources (UL1 RR0249139)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01-HD- 28016, R01HD028016, R01-HD40787, K24HD001464, R01HD040787, K24-HD01464)
  • Daiichi Sankyo Europe
  • Cilag
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, youth, childhood obesity, adolescents, prediabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, insulin secretion, beta-cell function, natural history (disease), diabetes prevalence, cardiovascular complications
MeSH terms
Adolescent, Diabetes Mellitus, Type 2, Female, Humans, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Type 2 Diabetes in Youth: Epidemiology and Pathophysiology. https://app.cochat.ai/papers/10.2337/dc11-s212
The paper
D’Adamo, E., & Caprio, S. (2011). Type 2 Diabetes in Youth: Epidemiology and Pathophysiology. Diabetes Care. https://doi.org/10.2337/dc11-s212

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.